PROVENTION BIO INC's ticker is PRVB and the CUSIP is 74374N102. A total of 65 filers reported holding PROVENTION BIO INC in Q1 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $5,434,382 | +93.9% | 225,493 | -15.0% | 0.00% | 0.0% |
| Q4 2022 | $2,802,445 | +191.0% | 265,132 | +23.9% | 0.00% | – |
| Q3 2022 | $963,000 | +39.6% | 214,030 | +24.2% | 0.00% | – |
| Q2 2022 | $690,000 | -54.0% | 172,358 | -15.9% | 0.00% | – |
| Q1 2022 | $1,500,000 | +23.8% | 204,913 | -5.0% | 0.00% | – |
| Q4 2021 | $1,212,000 | -17.2% | 215,763 | -5.6% | 0.00% | – |
| Q3 2021 | $1,463,000 | -12.2% | 228,569 | +15.6% | 0.00% | – |
| Q2 2021 | $1,667,000 | -11.8% | 197,799 | +9.9% | 0.00% | – |
| Q1 2021 | $1,890,000 | -36.8% | 180,029 | +1.9% | 0.00% | -100.0% |
| Q4 2020 | $2,992,000 | +35.9% | 176,639 | +3.0% | 0.00% | 0.0% |
| Q3 2020 | $2,201,000 | -3.2% | 171,516 | +6.4% | 0.00% | 0.0% |
| Q2 2020 | $2,274,000 | +998.6% | 161,172 | +616.1% | 0.00% | – |
| Q1 2020 | $207,000 | -70.8% | 22,506 | -52.6% | 0.00% | – |
| Q4 2019 | $708,000 | +763.4% | 47,506 | +293.3% | 0.00% | – |
| Q3 2019 | $82,000 | – | 12,078 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DG Capital Management, LLC | 287,172 | $4,052,000 | 3.32% |
| Johnson & Johnson Innovation - JJDC, Inc. | 1,124,973 | $15,873,000 | 3.12% |
| Perceptive Advisors | 4,525,711 | $63,858,000 | 1.04% |
| 683 Capital Management, LLC | 600,000 | $8,467,000 | 0.68% |
| Monashee Investment Management LLC | 250,000 | $3,528,000 | 0.53% |
| Soleus Capital Management, L.P. | 59,900 | $845,000 | 0.48% |
| EAM Global Investors LLC | 69,564 | $982,000 | 0.44% |
| EAM Investors, LLC | 54,020 | $762,000 | 0.17% |
| Virtus ETF Advisers LLC | 24,401 | $344,000 | 0.16% |
| GILDER GAGNON HOWE & CO LLC | 1,251,260 | $17,655,000 | 0.14% |